GE

Genexine, Inc.

Clinical-stage biotech developing long-acting therapeutics for oncology and rare diseases.

095700 | KO

Overview

Corporate Details

ISIN(s):
KR7095700001
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙로 172 바이오이노베이션파크, 강서구

Description

Genexine, Inc. is a clinical-stage biotechnology company focused on developing and commercializing immunotherapeutics and next-generation biologics. The company utilizes its proprietary hyFc® platform technology to create long-acting protein therapeutics. Its pipeline is led by GX-I7, a long-acting interleukin-7 designed to amplify T-cell counts for immuno-oncology applications. Other key assets in late-stage clinical trials include GX-E4, a long-acting treatment for anemia, and GX-H9 for growth hormone deficiency. Genexine's research and development efforts primarily target oncology and rare diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-12-18 00:00
투자판단관련주요경영사항(코로나바이러스감염증-19 (COVID-19) 예방백신 (GX-19) 임상 제1/2a상 임상시험 종료)
Korean 10.1 KB
2020-12-17 00:00
증권발행결과(자율공시)
Korean 5.6 KB
2020-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2020-12-15 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 28.8 KB
2020-12-14 00:00
타법인주식및출자증권취득결정(자율공시)
Korean 15.7 KB
2020-12-14 00:00
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Korean 70.9 KB
2020-12-14 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 35.7 KB
2020-12-11 00:00
주요사항보고서(유상증자결정)
Korean 27.0 KB
2020-12-11 00:00
주요사항보고서(전환사채권발행결정)
Korean 33.9 KB
2020-12-11 00:00
주요사항보고서(타법인주식및출자증권양수결정)
Korean 69.1 KB
2020-12-11 00:00
투자판단관련주요경영사항(건강한 성인을 대상으로 COVID-19 예방 DNA 백신 GX-19/GX-19N 의 제 1/2a 상 임상시험 계획 변경…
Korean 8.6 KB
2020-12-01 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2020-11-19 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 23.9 KB
2020-11-10 00:00
기업설명회(IR)개최
Korean 7.3 KB
2020-11-10 00:00
[기재정정]기업설명회(IR)개최
Korean 10.7 KB

Automate Your Workflow. Get a real-time feed of all Genexine, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genexine, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genexine, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.